JP2000327569A - Intraintestinal environment ameliorator - Google Patents
Intraintestinal environment amelioratorInfo
- Publication number
- JP2000327569A JP2000327569A JP11139567A JP13956799A JP2000327569A JP 2000327569 A JP2000327569 A JP 2000327569A JP 11139567 A JP11139567 A JP 11139567A JP 13956799 A JP13956799 A JP 13956799A JP 2000327569 A JP2000327569 A JP 2000327569A
- Authority
- JP
- Japan
- Prior art keywords
- bacteria
- intestinal
- acid
- useful
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、腸内のＰＨを弱酸
性域に調整し、腸内における乳酸菌、ビフィズス菌など
の有用菌の繁殖を促し、また悪玉菌を殺菌すると同時に
その繁殖を抑制して、腸内環境を改善するための腸内環
境改善剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention adjusts the pH of the intestine to a weakly acidic range, promotes the propagation of useful bacteria such as lactic acid bacteria and bifidobacteria in the intestine, and kills the bad bacteria while suppressing their growth. And an intestinal environment improving agent for improving the intestinal environment.
【０００２】[0002]
【従来の技術】我々人間の健康度や老化度は、腸の状況
に依存している部分があり、その状況次第で、その人の
寿命を左右するとまでいわれている。従来、乳酸菌やビ
フィズス菌などの腸内有用菌を腸溶性カプセルに内包し
たり、腸溶性基材とともに造粒した経口投与用の製剤が
知られている。これらは前記腸内有用菌を胃中で死滅さ
せることなく確実に腸にまで到達させることができ、こ
れにより腸内において有用菌を増殖させ、腸内環境を改
善しようとするものである。2. Description of the Related Art The degree of health and aging of human beings depends on the condition of the intestine, and it is said that the life of a person depends on the condition. Conventionally, preparations for oral administration in which useful enteric bacteria such as lactic acid bacteria and bifidobacteria are encapsulated in enteric capsules or granulated with enteric base materials are known. These are intended to ensure that the useful intestinal bacteria can reach the intestine without being killed in the stomach, thereby increasing the useful bacteria in the intestine and improving the intestinal environment.
【０００３】前記のような乳酸菌やビフィズス菌などの
腸内有用菌は、ＰＨ５〜６．５程度の弱酸性領域で最も
よく繁殖する。人間の正常な腸内は弱酸性であるため、
本来、前記のような有用菌が繁殖しやすい状況にある。
しかし、近年における西洋型の食習慣への移行や、スト
レス、間食、偏食、酒やタバコの飲み過ぎや吸い過ぎ、
更には睡眠不足などによって、膵臓液の分泌が活発にな
り、結果として腸内のＰＨがアルカリ領域へ移行してし
まう。このように腸内ＰＨがアルカリ領域の状況では、
せっかく摂取した乳酸菌やビフィズス菌などの腸内有用
菌の繁殖が阻害されるだけでなく、クロストリジュウム
・パークリンジェンス（通称ウエルシュ菌）に代表され
る悪玉菌、日和見菌、例えば、大腸菌、腸球菌、バクテ
ロイデス、クレブシュエラ、嫌気性レンサ球菌、ブドウ
球菌、ヘモフィルス、マイコプラズマ、プロテウスなど
の繁殖が活発化し、便秘などによって腸内において硫化
水素、インドール、スカトール、メタンガス、アンモニ
ア、ヒスタミン、ニトロソアミンなどの老廃物の貯留が
起こり、下痢や便秘などの症状を伴い、腸内腐敗、細菌
による毒素や発癌性物質の産生などが起こる。その結果
として発育障害、肝臓障害、動脈硬化、高血圧、癌、自
己免疫疾患などの諸障害が発生し、健康が阻害される。
また、その一方で、膀胱炎、腎炎、髄膜炎、肝膿瘍、肺
膿瘍、脳膿瘍、腹膜炎、敗血症などの病気への直接罹患
原因ともなりかねない。[0003] Intestinal useful bacteria such as the lactic acid bacteria and bifidobacteria described above proliferate best in a weakly acidic region of about PH5 to 6.5. Because the normal intestines of humans are weakly acidic,
Originally, there is a situation where the useful bacteria as described above are easy to propagate.
However, in recent years, there has been a shift to western-style eating habits, stress, snacks, unbalanced eating, drinking and smoking too much,
Furthermore, due to lack of sleep and the like, the secretion of pancreatic juice becomes active, and as a result, PH in the intestine shifts to an alkaline region. Thus, in the situation where the intestinal PH is in the alkaline region,
In addition to inhibiting the growth of intestinal useful bacteria such as lactic acid bacteria and bifidobacteria that have been ingested, bad bacteria and opportunistic bacteria such as Clostridium perclingens (commonly known as Welsh bacteria) such as Escherichia coli and enterococci , Bacteroides, Klebsiella, anaerobic streptococci, staphylococci, hemophilus, mycoplasma, proteus, etc., have become more active. Storage occurs, accompanied by symptoms such as diarrhea and constipation, intestinal rot, bacterial production of toxins and carcinogens, and the like. As a result, various disorders such as developmental disorders, liver disorders, arteriosclerosis, hypertension, cancer, and autoimmune diseases occur, and health is impaired.
On the other hand, it may directly cause diseases such as cystitis, nephritis, meningitis, liver abscess, lung abscess, brain abscess, peritonitis, and sepsis.
【０００４】[0004]
【発明が解決しようとする課題】上記のように、腸の状
況は人間の健康にとって非常に大切であるにもかかわら
ず、必ずしも健康な状況にあるとはいい難い。そこで本
発明の目的は、腸内環境を改善することで、健康増進を
図らんとするものである。As described above, although the condition of the intestine is very important for human health, it is difficult to say that the condition is healthy. Therefore, an object of the present invention is to promote health by improving the intestinal environment.
【０００５】[0005]
【課題を解決するための手段】本発明は、ウエルシュ菌
や大腸菌といった悪玉菌は乳酸や酢酸などの有機酸によ
って死滅し、また、腸内を弱酸性に保つことでこれら悪
玉菌の繁殖が抑制されると同時に、乳酸菌やビフィズス
菌などの腸内有用菌の繁殖が促進され、腸内を健康な環
境にしうるとの知見に基づくものである。すなわち、本
発明は、有機酸を腸溶性カプセルに内包してなる腸内環
境改善剤に係るものである。さらに、本発明は、有機酸
とともにオリゴ糖を腸溶性カプセルに内包した腸内環境
改善剤に係るものである。前記有機酸としては、乳酸、
クエン酸及び酢酸を好ましいものとして挙げることがで
きる。これらの有機酸は単独で使用してもよいし、複数
のものを併用することもできる。According to the present invention, bad bacteria such as Welsh bacteria and Escherichia coli are killed by organic acids such as lactic acid and acetic acid, and the growth of these bad bacteria is suppressed by keeping the intestine weakly acidic. At the same time, it is based on the finding that the propagation of useful intestinal bacteria such as lactic acid bacteria and bifidobacteria is promoted and the intestine can be made healthy. That is, the present invention relates to an intestinal environment improving agent comprising an organic acid encapsulated in an enteric capsule. Furthermore, the present invention relates to an intestinal environment improving agent in which an oligosaccharide is contained in an enteric capsule together with an organic acid. As the organic acid, lactic acid,
Citric acid and acetic acid can be mentioned as preferred. These organic acids may be used alone or in combination of two or more.
【０００６】[0006]
【発明の実施の形態】上記のように、本発明に係る腸内
環境改善剤は、乳酸、クエン酸、酢酸などの有機酸を腸
溶性カプセルに内包してなるものであるが、ここで用い
る腸溶性カプセルとしては従来公知のものでよい。例え
ばカルボキシメチルセルロース、ヒドロキシメチルセル
ロース、ツェイン、アルギン酸ナトリウム、シェラック
などの従来公知の腸溶性皮膜基材を用い、従来公知のカ
プセル製造装置および製造方法により製造することがで
きる。カプセルの形態も、ロータリー式製造法や回転ド
ラムを用いた打ち抜き法による軟カプセル、またはカプ
セル形成用型を皮膜形成基材溶液に浸漬して型に付着さ
せた基材を乾燥させて皮膜を形成してなる硬カプセル、
さらには滴下法、ノズルオリフィス法、振動法などによ
り製造されるシームレスカプセルのいずれであってもよ
い。また、ゼラチンを主原料として製造した軟カプセル
の表面に前記のような腸溶性皮膜基材をコーティングし
たものや、さらには、ゼラチンを主原料とする軟カプセ
ル皮膜基材にカラギーナン、アルギン酸ナトリウムなど
を配合して腸溶性とした皮膜基材からなるカプセルであ
ってもよく、胃中で溶解することなく、内包した有機酸
などを確実に腸にまで到達せしめることができるもので
あれば、カプセルの形態や種類には制限はない。例え
ば、日本薬局方に規定される腸溶性軟カプセルの性質を
有するもの、すなわち、日本薬局方崩壊試験器中におい
て、日本薬局方第一液（人工胃液）には容易に溶解せ
ず、同第二液（人工腸液）に容易に溶解するものであれ
ばよい。BEST MODE FOR CARRYING OUT THE INVENTION As described above, the intestinal environment improving agent according to the present invention contains an organic acid such as lactic acid, citric acid, or acetic acid in an enteric capsule, and is used here. A conventionally known enteric capsule may be used. For example, it can be manufactured using a conventionally known enteric coating base material such as carboxymethylcellulose, hydroxymethylcellulose, zein, sodium alginate, shellac and the like by a conventionally known capsule manufacturing apparatus and manufacturing method. The form of the capsule is also formed by soft coating by a rotary manufacturing method or punching method using a rotating drum, or by dipping a mold for forming a capsule in a film forming substrate solution and drying the substrate adhered to the mold to form a film. Hard capsule
Further, any of seamless capsules manufactured by a dropping method, a nozzle orifice method, a vibration method, or the like may be used. In addition, the surface of a soft capsule produced using gelatin as a main material is coated with the enteric film substrate as described above, and further, carrageenan, sodium alginate and the like are coated on a soft capsule film substrate using gelatin as a main material. It may be a capsule consisting of an enteric coating base material that has been blended, and if it is capable of ensuring that the encapsulated organic acids etc. can reach the intestine without dissolving in the stomach, There are no restrictions on the form or type. For example, those having the properties of an enteric-coated soft capsule specified in the Japanese Pharmacopoeia, that is, in a Japanese Pharmacopoeia disintegration tester, they do not easily dissolve in the Japanese Pharmacopoeia first liquid (artificial gastric juice), Any solution that can be easily dissolved in two solutions (artificial intestinal fluid) may be used.
【０００７】ところで、腸内ＰＨを調整するために乳酸
やクエン酸などを直接経口投与することも考えられる
が、この場合には膵液の影響をもろに受けてしまい、腸
内ＰＨを調整することは困難である。これ対し、本発明
では、乳酸、クエン酸などの有機酸を腸溶性皮膜基材に
より作成した腸溶性カプセル、または表面に腸溶性皮膜
基材をコーティングした腸溶性カプセルに内包すること
で、これを経口投与した場合に膵液の影響を受けること
なく、前記有機酸を確実に腸へ到達せしめ、悪玉菌を死
滅させると同時に腸内ＰＨを弱酸性領域に調整すること
ができる。In order to adjust the intestinal pH, it is conceivable to directly orally administer lactic acid, citric acid, or the like. In this case, however, the intestinal pH is affected by pancreatic juice. It is difficult. On the other hand, in the present invention, an organic acid such as lactic acid or citric acid is encapsulated in an enteric capsule prepared from an enteric coating substrate or in an enteric capsule coated on the surface with an enteric coating substrate. When administered orally, the organic acid can surely reach the intestine without being affected by pancreatic juice, killing bad bacteria and simultaneously adjusting the intestinal pH to a weakly acidic region.
【０００８】本発明に用いられる有機酸としては、腸内
ＰＨを弱酸性領域に調整することができ、かつ人体に悪
影響を及ぼすおそれがなければどのようなものであって
もよいが、乳酸やクエン酸はウエルシュ菌やブドウ球菌
などの悪玉菌に直接作用してこれを殺菌することができ
ることから本発明で使用する有機酸として好ましいもの
である。また、クエン酸は人体に最も有益な酸であり、
クエン酸サイクルに寄与することからも好ましい。さら
に、酢酸も同様に悪玉菌を殺菌する作用を有することか
ら好ましい。その他の有機酸としては、シュウ酸やリン
ゴ酸も人体に対する悪影響はなく使用することができ
る。これらの有機酸は単独で使用してもよく、また複数
のものを併用してもよい。１カプセル中におけるこれら
有機酸の充填量には特に制限はないが、通常の場合は数
１０ｍｇ〜数１００ｍｇ程度である。また、１日当たり
の投与量も特に制限はないが、目安としては、有機酸と
して数１００ｍｇ〜数ｇである。As the organic acid used in the present invention, any organic acid can be used as long as it can adjust the intestinal pH to a weakly acidic region and has no adverse effect on the human body. Citric acid is preferred as the organic acid used in the present invention because it can act directly on bad bacteria such as Welsh bacteria and staphylococci to kill them. Also, citric acid is the most beneficial acid for the human body,
It is also preferable because it contributes to the citric acid cycle. Furthermore, acetic acid is also preferable because it has an action of sterilizing bad bacteria. As other organic acids, oxalic acid and malic acid can be used without any adverse effect on the human body. These organic acids may be used alone or in combination of two or more. The filling amount of these organic acids in one capsule is not particularly limited, but is usually several tens mg to several hundred mg in a normal case. Also, the daily dose is not particularly limited, but the standard is several hundred mg to several g as an organic acid.
【０００９】更に、本発明の腸内環境改善剤には、上記
のような有機酸に加えてオリゴ糖を併用することができ
る。このオリゴ糖は、乳酸菌やビフィズス菌といった腸
内有用菌の栄養源となるものであり、これを上記のよう
な乳酸、クエン酸および酢酸などの有機酸とともに直接
腸内へ送り込むことにより、有機酸によりウエルシュ
菌、ブドウ球菌などの悪玉菌が殺菌され、且つ腸内ＰＨ
が弱酸性領域に調整されることで悪玉菌の繁殖が抑制さ
れると同時に乳酸菌やビフィズス菌などの腸内有用菌が
繁殖しやすい腸内環境を実現し、このような腸内環境下
で前記腸内有用菌に対して栄養源であるオリゴ糖が供給
されることで、腸内環境改善効果がより一層向上する。
本発明で使用するオリゴ糖としては特に限定はないが、
例えば大豆オリゴ糖、イソマントオリゴ糖、ガラクトオ
リゴ糖などが挙げられる。Furthermore, the intestinal environment improving agent of the present invention can use an oligosaccharide in addition to the above-mentioned organic acids. This oligosaccharide is a nutrient source for intestinal useful bacteria such as lactic acid bacteria and bifidobacteria, and is directly fed into the intestine together with the above-mentioned organic acids such as lactic acid, citric acid and acetic acid, thereby producing an organic acid. Bad bacteria such as welsh fungi and staphylococci are killed by
By adjusting to a weakly acidic region, the growth of bad bacteria is suppressed and at the same time, an intestinal environment in which useful intestinal bacteria such as lactic acid bacteria and bifidobacteria are proliferated is realized. By supplying oligosaccharides as a nutrient source to useful intestinal bacteria, the intestinal environment improving effect is further improved.
The oligosaccharide used in the present invention is not particularly limited,
For example, soybean oligosaccharides, isomantooligosaccharides, galacto-oligosaccharides and the like can be mentioned.
【００１０】さらに、本発明に係る腸内環境改善剤に
は、上記の有機酸、オリゴ糖に加えて、乳酸菌やビフィ
ズス菌などの腸内有用菌を同時に腸溶性カプセルに内包
しておくことができる。この場合には、有機酸により改
善される腸内環境において、これらの有用菌が活発に繁
殖し、腸内環境がより一層改善される。この乳酸菌やビ
フィズス菌などを併用する場合には、有機酸としては乳
酸やクエン酸のような粉体状の酸を用いることが好まし
い。また、併用する乳酸菌の具体例としては、L.アシド
フィルス、L.ブランタルム、L.ブレビス、L.サリバリウ
スなどが挙げられ、ビフィズス菌の具体例としては、B.
インファンティス、B.ロンガム、B.ブレーベ、B.アドレ
ッセンティスなどが挙げられる。また、本発明の腸内環
境改善剤と、乳酸菌やビフィズス菌などの腸内有用菌を
腸溶性カプセルに内包したものとを同時に服用すること
でも、上記と同様の効果を得ることができる。[0010] In addition, the intestinal environment improving agent according to the present invention may contain useful enteric bacteria such as lactic acid bacteria and bifidobacteria in addition to the above-mentioned organic acids and oligosaccharides in an enteric capsule at the same time. it can. In this case, these useful bacteria actively propagate in the intestinal environment improved by the organic acid, and the intestinal environment is further improved. When lactic acid bacteria and bifidobacteria are used in combination, it is preferable to use a powdered acid such as lactic acid or citric acid as the organic acid. Specific examples of the lactic acid bacteria used in combination include L. acidophilus, L. blantalum, L. brevis, L. salivarius, and the like.Specific examples of the bifidobacteria include B.
Infantis, B. Longum, B. Breve, B. Addressentis and the like. The same effects as described above can also be obtained by simultaneously taking the intestinal environment-improving agent of the present invention and an enteric capsule containing useful enteric bacteria such as lactic acid bacteria and bifidobacteria.
【００１１】[0011]
【実施例】ゼラチン４０ｋｇ、グリセリン１２ｋｇ、精
製水３６ｋｇを混合し、６０℃で溶解した後、真空脱気
してカプセル被膜基材溶液を得た。一方、サフラワー油
１９８０ｇにミツロウ２１０ｇ、グリセリン脂肪酸エス
テル２１０ｇを加え、約８０℃に加温して溶解した後、
２５℃まで冷却し、これに乳酸１５０ｇ、クエン酸１５
０ｇ、酢酸１５０ｇおよびイソマントオリゴ糖１５０ｇ
を加えて均一に混合した後、真空脱気してカプセル内容
液３０００ｇを得た。前記の被覆基材溶液と内容液と
を、ロータリー式軟カプセル製造機に仕込み、常法によ
りカプセル内容液５００ｍｇを内包したフットボール型
の軟カプセルを製造した（このカプセル１粒には、乳酸
２５ｍｇ、クエン酸２５ｍｇ、酢酸２５ｍｇおよびイソ
マントオリゴ糖２５ｍｇが含まれている）。次に、エタ
ノール７００ｇ、ツェイン１００ｇおよび精製水２００
ｇを混合溶解して腸溶性コーティング液を得た。前記軟
カプセル５００ｇをコーティング装置（フロイント産業
製；ＨＣＴ−ＭＩＮＩ）に仕込み、上記のコーティング
液を連続噴霧し、軟カプセル重量が１５％増加するまで
コーティングを行い、本発明に係る腸内環境改善剤であ
る腸溶性カプセルを得た。得られた腸溶性カプセルを日
本薬局方に規定される腸溶性製剤の崩壊試験法により試
験したところ、これに適合することが確認できた。即
ち、前記腸内環境改善剤が腸溶性であることが確認でき
た。EXAMPLE 40 kg of gelatin, 12 kg of glycerin and 36 kg of purified water were mixed and dissolved at 60 ° C., followed by degassing under vacuum to obtain a capsule coating substrate solution. On the other hand, 210 g of beeswax and 210 g of glycerin fatty acid ester were added to 1980 g of safflower oil and dissolved by heating to about 80 ° C.
Cool to 25 ° C, add 150 g of lactic acid, 15 citric acid
0 g, 150 g of acetic acid and 150 g of isomantooligosaccharide
Was added and mixed uniformly, followed by degassing under vacuum to obtain 3000 g of a capsule content liquid. The coated base material solution and the content liquid were charged into a rotary soft capsule manufacturing machine, and a football-type soft capsule containing 500 mg of the capsule content liquid was manufactured by an ordinary method (25 mg of lactic acid per capsule). 25 mg of citric acid, 25 mg of acetic acid and 25 mg of isomantooligosaccharide). Next, 700 g of ethanol, 100 g of zein, and 200
g was mixed and dissolved to obtain an enteric coating solution. 500 g of the soft capsule is charged into a coating apparatus (manufactured by Freund Corporation; HCT-MINI), and the above coating liquid is continuously sprayed to coat the soft capsule until the weight of the soft capsule increases by 15%. Was obtained. When the obtained enteric capsule was tested by the disintegration test method of the enteric preparation prescribed in the Japanese Pharmacopoeia, it was confirmed that the capsule was compatible. That is, it was confirmed that the intestinal environment improving agent was enteric.
【００１２】上記のようにして製造した腸内環境改善剤
について、以下のような実験を行った。The following experiments were conducted on the intestinal environment improving agent produced as described above.
【００１３】健康な１８人を３群に分け、第Ｉ群の６人
には上記の腸溶性カプセル入り腸内環境改善剤を１日当
たり２カプセル、第II群の６人には１日当たり３カプセ
ル、第III群の６人には１日当たり４カプセルを、それ
ぞれ３週間経口投与し、糞便中のビフィズス菌と他の腸
内細菌の割合を調べた。その結果を表１に示す。なお、
カプセル投与前における被験者の糞便中のビフィズス菌
は１８〜２１％、他の腸内細菌は２８〜３４％である。The 18 healthy persons were divided into three groups. Six persons in Group I received two capsules per day of the enteric environment-improving agent containing the enteric capsule, and six persons in Group II received three capsules per day. Six capsules of Group III were orally administered 4 capsules per day for 3 weeks each, and the proportions of bifidobacteria and other intestinal bacteria in feces were examined. Table 1 shows the results. In addition,
Bifidobacterium in the feces of the test subject before capsule administration is 18-21%, and other intestinal bacteria are 28-34%.
【００１４】[0014]
【表１】 [Table 1]
【００１５】表１の結果から明らかなように、本発明に
係る腸内環境改善剤を経口投与することにより、腸内細
菌の分布に顕著な影響が見られ、明らかにビフィズス菌
優勢の菌叢になっていることが認められた。また、投与
中止１週間後の菌叢においては、各群において、ほぼカ
プセル投与開始時の状態に近い菌叢に戻っている。この
結果から、本発明に係る腸内環境改善剤が腸内菌叢に直
接関与して、ビフィズス菌など人体に有用な菌の増加に
大変有効であることが明らかとなった。As is evident from the results in Table 1, the oral administration of the intestinal environment-improving agent according to the present invention has a remarkable effect on the distribution of intestinal bacteria, and the biflora-dominant flora is clearly dominant. It was recognized that it was. In addition, in the microflora one week after the administration was stopped, the microflora in each group returned to the microflora almost similar to the state at the start of capsule administration. From these results, it has been clarified that the intestinal environment-improving agent according to the present invention is directly involved in the intestinal flora and is very effective in increasing bacteria useful for the human body such as bifidobacteria.
【００１６】[0016]
【発明の効果】以上のように、本発明に係る腸内環境改
善剤によれば、腸内の悪玉菌を殺菌するとともに、悪玉
菌が繁殖し難く有用菌が繁殖しやすい環境に改善するこ
とができる。As described above, according to the intestinal environment improving agent of the present invention, it is possible to sterilize intestinal bad bacteria and improve the environment in which bad bacteria hardly propagate and useful bacteria easily propagate. Can be.
───────────────────────────────────────────────────── フロントページの続き Ｆターム(参考） 4C076 AA53 AA56 BB01 CC16 DD09H DD37A DD37H DD38A DD38H DD41Z DD43Z DD46 DD46A DD67 DD67A EE42H EE53A EE53F EE55A FF25 4C206 AA01 AA02 DA02 DA36 MA01 MA02 MA04 MA28 MA57 MA72 NA14 ZA66 ZA73 ──────────────────────────────────────────────────続 き Continued on the front page F term (reference) 4C076 AA53 AA56 BB01 CC16 DD09H DD37A DD37H DD38A DD38H DD41Z DD43Z DD46 DD46A DD67 DD67A EE42H EE53A EE53F EE55A FF25 4C206 AA01 AA02 DA02 DA36 MA01 MA02 MA04 MA04
Claims (3)
腸内環境改善剤。1. An intestinal environment improving agent comprising an organic acid encapsulated in an enteric capsule.
ルに内包してなる腸内環境改善剤。2. An intestinal environment improving agent comprising an oligosaccharide in an enteric capsule together with an organic acid.
る群から選択される少なくとも１種である請求項１また
は２に記載の腸内環境改善剤。3. The intestinal environment improving agent according to claim 1, wherein the organic acid is at least one selected from the group consisting of lactic acid, citric acid and acetic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11139567A JP2000327569A (en) | 1999-05-20 | 1999-05-20 | Intraintestinal environment ameliorator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11139567A JP2000327569A (en) | 1999-05-20 | 1999-05-20 | Intraintestinal environment ameliorator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2000327569A true JP2000327569A (en) | 2000-11-28 |
Family
ID=15248286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11139567A Pending JP2000327569A (en) | 1999-05-20 | 1999-05-20 | Intraintestinal environment ameliorator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2000327569A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2838350A1 (en) * | 2002-04-15 | 2003-10-17 | Georges Serge Grimberg | Gastro-resistant compositions for treatment of constipation comprise liquid lactic acid on a solid support |
| JP2009196961A (en) * | 2008-02-25 | 2009-09-03 | Qualicaps Co Ltd | Enteric capsule |
| WO2012015323A1 (en) * | 2010-07-28 | 2012-02-02 | Biolek Sp. Z O.O. | Use of a mixture of probiotic bacteria in a mixture with short - chain fatty acids |
| JP2015507629A (en) * | 2011-12-29 | 2015-03-12 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | Compositions and methods for improving gastrointestinal flora |
| JP2017002053A (en) * | 2016-06-30 | 2017-01-05 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | Compositions and methods for modifying gastrointestinal flora |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0223848A (en) * | 1988-07-11 | 1990-01-26 | Ishi Kiuchi | Method for enhacing propagation of enteral lactobacillus bifidus or the line with oligosaccharides or the like |
| JPH0482827A (en) * | 1990-07-23 | 1992-03-16 | Snow Brand Milk Prod Co Ltd | Entero-soluble capsule |
| JPH1029945A (en) * | 1996-07-17 | 1998-02-03 | Snow Brand Milk Prod Co Ltd | Enteric metabolism-improving agent |
| JPH10108672A (en) * | 1996-10-04 | 1998-04-28 | Meiji Milk Prod Co Ltd | Activity potentiating and stabilizing agent for bifidus factor |
| JPH10236956A (en) * | 1997-02-28 | 1998-09-08 | Nippon Beet Sugar Mfg Co Ltd | Immunopotentiator |
| JPH10306028A (en) * | 1997-05-06 | 1998-11-17 | Koji Haraguchi | Drug for controlling intestinal function by lipid digestive absorbent inhibition |
| JPH10327900A (en) * | 1997-06-02 | 1998-12-15 | Agency Of Ind Science & Technol | Production of water-soluble oligosaccharides and monosaccharides |
| JPH1175687A (en) * | 1997-09-04 | 1999-03-23 | Yakult Honsha Co Ltd | Production of soybean milk fermentation food product |
-
1999
- 1999-05-20 JP JP11139567A patent/JP2000327569A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0223848A (en) * | 1988-07-11 | 1990-01-26 | Ishi Kiuchi | Method for enhacing propagation of enteral lactobacillus bifidus or the line with oligosaccharides or the like |
| JPH0482827A (en) * | 1990-07-23 | 1992-03-16 | Snow Brand Milk Prod Co Ltd | Entero-soluble capsule |
| JPH1029945A (en) * | 1996-07-17 | 1998-02-03 | Snow Brand Milk Prod Co Ltd | Enteric metabolism-improving agent |
| JPH10108672A (en) * | 1996-10-04 | 1998-04-28 | Meiji Milk Prod Co Ltd | Activity potentiating and stabilizing agent for bifidus factor |
| JPH10236956A (en) * | 1997-02-28 | 1998-09-08 | Nippon Beet Sugar Mfg Co Ltd | Immunopotentiator |
| JPH10306028A (en) * | 1997-05-06 | 1998-11-17 | Koji Haraguchi | Drug for controlling intestinal function by lipid digestive absorbent inhibition |
| JPH10327900A (en) * | 1997-06-02 | 1998-12-15 | Agency Of Ind Science & Technol | Production of water-soluble oligosaccharides and monosaccharides |
| JPH1175687A (en) * | 1997-09-04 | 1999-03-23 | Yakult Honsha Co Ltd | Production of soybean milk fermentation food product |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2838350A1 (en) * | 2002-04-15 | 2003-10-17 | Georges Serge Grimberg | Gastro-resistant compositions for treatment of constipation comprise liquid lactic acid on a solid support |
| JP2009196961A (en) * | 2008-02-25 | 2009-09-03 | Qualicaps Co Ltd | Enteric capsule |
| WO2012015323A1 (en) * | 2010-07-28 | 2012-02-02 | Biolek Sp. Z O.O. | Use of a mixture of probiotic bacteria in a mixture with short - chain fatty acids |
| JP2015507629A (en) * | 2011-12-29 | 2015-03-12 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | Compositions and methods for improving gastrointestinal flora |
| JP2017002053A (en) * | 2016-06-30 | 2017-01-05 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | Compositions and methods for modifying gastrointestinal flora |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK170922B1 (en) | Cefaclor formulation with long lasting effect | |
| JP3752421B2 (en) | Fine enteric coated granules for stabilization of lactic acid bacteria | |
| JP5400997B2 (en) | Use of a composition comprising minerals and, in some cases, acetic acid producing bacteria and / or butyric acid producing bacteria, to avoid or reduce gas generation in the large intestine of mammals and abdominal symptoms resulting therefrom | |
| JP5394235B2 (en) | Food composition for binding acetaldehyde | |
| CN102256610A (en) | Probiotic formulations | |
| JP2000509367A (en) | Use of lactoperoxidase, peroxide donor and thiocyanate for the manufacture of a medicament for the treatment of Helicobacter pylori infection | |
| EP2542223B1 (en) | Complex formulation for oral administration comprising probiotic formulation and 5-ht4 receptor agonist and method for the preparation thereof | |
| US9056122B2 (en) | Method for inhibition of blood phosphorus level elevation | |
| KR20020031383A (en) | Oral form of administration containing probiotic micro-organisms | |
| EP1566176B1 (en) | Synergistic antibacterial formulation and a method of making the same | |
| CN102231988A (en) | Pharmaceutical preparation comprising lipase of bacterial origin | |
| JPH08242763A (en) | Yogurt containing capsuled useful enteral bacterium | |
| JPH0441434A (en) | Lactobacillus tablet provided with enteric coating | |
| CN112121067A (en) | Bifidobacterium infantis microcapsule and preparation method thereof | |
| JPS61151127A (en) | Production of soft capsule containing bifidus bacteria | |
| JP2000327569A (en) | Intraintestinal environment ameliorator | |
| JPH11302158A (en) | Health food having intestinal function controlling action and produced by using enteric seam capsule | |
| RU2182008C1 (en) | Perorally, rectally or intravaginally injected composition containing alive bacteria | |
| JPH09154535A (en) | Natto (fermented soybean)-containing composition | |
| US20100203125A1 (en) | Synergistic antibacterial formulation and a method of making the same | |
| JP2013224273A (en) | Enteric environment improving dry-coated tablet formulation and hard capsule formulation | |
| RU2325166C1 (en) | Pharmaceutical formulation of antibiotics and lactulose applied for prevention of enteral disbiosis caused by antibiotic therapy | |
| WO2018125735A1 (en) | Composition and method for maintaining healthy kidney function | |
| JP2004250338A (en) | Useful live bacterium pharmaceutical preparation | |
| RU2325187C1 (en) | Pharmaceutical formulation of antibiotics and prebiotics (versions) applied for prevention and medical treatment of disbioses caused by antibacterial therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040511 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040709 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050809 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20051101 |